Prime Medicine, Inc.PRMENASDAQ
Loading
EV to Sales: Premium ValuationElevated
Percentile Rank83
5Y CAGR-14.9%
Studio
Year-over-Year Change

Enterprise value to sales ratio

5Y CAGR
-14.9%/yr
Long-term compound
Percentile
P83
Within normal range
vs 5Y Ago
0.4x
Contraction
Streak
2 yr
Consecutive growthElevated
PeriodValueYoY Change
2025122.97+79.3%
202468.60-
20230.00-
20220.00-
20210.00-100.0%
2020275.32-
20190.00-